Revvity AlphaLISA SureFire Ultra Human Phospho-BCKDHA (Ser292) Detection Kit, 10,000 Assay Points

Branched-Chain Ketoacid Dehydrogenase E1-Alpha (BCKDHA) is the catalytic subunit of the BCKDC complex, which catalyzes the irreversible decarboxylation of branched-chain ketoacids derived from leucine, isoleucine, and valine. BCKDHA represents the rate-limiting step in branched-chain amino acid catabolism and is predominantly expressed in liver, muscle, kidney, and brain. Mutations in BCKDHA cause maple syrup urine disease (MSUD), characterized by accumulation of toxic ketoacid derivatives leading to neurological damage. MSUD severity varies depending on residual enzyme activity, ranging from classic severe forms to intermediate variants. Altered BCKDHA expression has been implicated in cancer metabolism, diabetes, and cardiovascular disease.

The AlphaLISA SureFire Ultra Human Phospho-BCKDHA (Ser292) is a sandwich immunoassay for the quantitative detection of phospho-BCKDHA (Ser292) in cellular lysates, using Alpha Technology.

Formats:

• The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
• The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
• The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
• The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.

AlphaLISA SureFire Ultra kits are compatible with:

• Cell and tissue lysates
• Antibody modulators
• Biotherapeutic antibodies

AlphaLISA SureFire Ultra kits can be used for:

• Cellular kinase assays
• Receptor activation studies
• High-throughput screening for preclinical studies